EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

S100A14 as a Potential Biomarker of the Colorectal Serrated Neoplasia Pathway

Pierre Adam iD, Catherine Salée, Florence Quesada Calvo, Arnaud Lavergne, Angela-Maria Merli, Charlotte Massot, Noëlla Blétard, Joan Somja iD, Dominique Baiwir iD, Gabriel Mazzucchelli iD, Carla Coimbra Marques, Philippe Delvenne und 2 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Pierre Adam und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Translational Gastroenterology, GIGA Institute, University of Liège, 4000 Liège, Belgium. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Biomarkers, Tumor, Adenoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fund for Scientific Research, Fonds Léon Fredericq, HOMISTASIS PROJECT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accounting for 15–30% of colorectal cancer cases, the serrated pathway remains poorly characterized compared to the adenoma–carcinoma sequence. It involves sessile serrated lesions as precursors and is characterized by BRAF mutations (BRAFV600E), CpG island hypermethylation, and microsatellite instability (MSI). Using label-free proteomics, we compared normal tissue margins from patients with diverticular disease, sessile serrated lesions, low-grade adenomas, and high-grade adenomas. We identified S100A14 as significantly overexpressed in sessile serrated lesions compared to low-grade adenomas, high-grade adenomas, and normal tissues. This overexpression was confirmed by immunohistochemical scoring in an independent cohort. Gene expression analyses of public datasets showed higher S100A14 expression in BRAFV600E-mutated and MSI-H colorectal cancers compared to microsatellite stable BRAFwt tumors. This finding was confirmed by immunohistochemical scoring in an independent colorectal cancer cohort. Furthermore, single-cell RNA sequencing analysis from the Human Colon Cancer Atlas revealed that S100A14 expression in tumor cells positively correlated with the abundance of tumoral CD8+ cytotoxic T cells, particularly the CD8+ CXCL13+ subset, known for its association with a favorable response to immunotherapy. Collectively, our results demonstrate for the first time that S100A14 is a potential biomarker of serrated neoplasia and further suggests its potential role in predicting immunotherapy responses in colorectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBiomarkers, TumorAdenomaHumansMicrosatellite InstabilityProto-Oncogene Proteins B-rafFemaleMaleGene Expression Regulation, NeoplasticMutationMiddle AgedAged

Stichwörter der Autor:innen

S100A14biomarkerproteomicsserrated pathwaysessile serrated lesions

Substanzen

Biomarkers, TumorProto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Laboratory of Translational Gastroenterology, GIGA Institute, University of Liège, 4000 Liège, Belgium.
  • GIGA Bioinformatics, GIGA Institute, University of Liège, 4000 Liège, Belgium.
  • Hepato-Gastroenterology and Digestive Oncology, University Hospital of Liège (CHU), 4000 Liège, Belgium.
  • Pathological Anatomy and Cytology, University Hospital of Liège (CHU), 4000 Liège, Belgium.
  • GIGA Proteomics, GIGA Institute, University of Liège, 4000 Liège, Belgium.
  • Laboratory of Mass Spectrometry, University of Liège, 4000 Liège, Belgium.

ORCID-Profile: Pierre Adam, Joan Somja, Dominique Baiwir, Gabriel Mazzucchelli, Marie-Alice Meuwis

Förderung

  • Fund for Scientific Research
  • Fonds Léon Fredericq
  • HOMISTASIS PROJECT
  • University of Liège
  • CHU of Liège grants
  • Dr. Falk Pharma
  • Celltrion
  • Fresenius Kabi

Zitieren

APA

Adam, P., Salée, C., Quesada Calvo, F., Lavergne, A., Merli, A. M., Massot, C., Blétard, N., Somja, J., Baiwir, D., Mazzucchelli, G., Coimbra Marques, C., Delvenne, P., Louis, E., & Meuwis, M. A. (2025). S100A14 as a Potential Biomarker of the Colorectal Serrated Neoplasia Pathway. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157401

Vancouver

Adam P, Salée C, Quesada Calvo F, Lavergne A, Merli AM, Massot C, et al. S100A14 as a Potential Biomarker of the Colorectal Serrated Neoplasia Pathway. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157401

BibTeX
@article{Adam2025,
  author = {Adam, Pierre and Salée, Catherine and Quesada Calvo, Florence and Lavergne, Arnaud and Merli, Angela-Maria and Massot, Charlotte and Blétard, Noëlla and Somja, Joan and Baiwir, Dominique and Mazzucchelli, Gabriel and Coimbra Marques, Carla and Delvenne, Philippe and Louis, Edouard and Meuwis, Marie-Alice},
  title = {S100A14 as a Potential Biomarker of the Colorectal Serrated Neoplasia Pathway},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157401}
}
Kostenlos starten →